Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +75

MiniMed expands Abbott partnership to add dual glucose-ketone sensor

AI-generated analysis

📈 MiniMed hosted its first earnings call as a publicly traded company since going public in March.

💉 The firm is transforming its product portfolio with plans for a patch pump and an algorithm that doesn't require meal announcements.

🤝 MiniMed is expanding its collaboration with Abbott to develop dual glucose-ketone sensors for integration with smart dosing systems.

⚠️ Abbott received Europe's CE mark for the dual sensor but has not yet received FDA clearance.

💰 MiniMed launched its smaller durable insulin pump, MiniMed Flex, which received FDA clearance in March and will launch later this month.

📝 The company also launched MiniMed Go, a system combining a smart insulin pen with a glucose sensor, last week in the U.S.

🔬 MiniMed is developing an automated insulin delivery algorithm called Vivera that removes the need for meal announcements or carbohydrate counting.

🏥 Enrollment in the U.S. pivotal trial for Vivera began in February and is now halfway to its target.

🧩 CEO Que Dallara stated the company is in the middle of a complete portfolio transformation focused on patient-requested products.

🔋 MiniMed aims to compete with Insulet in the patch-pump market, expecting to submit the device to the FDA this fall.

🏭 The company plans a commercial launch for the patch pump next year while scaling up production capacity.

📉 CFO Chad Spooner noted MiniMed currently has about 160 transitional service agreements with its former parent, Medtronic.

🗓️ Most of the transitional service agreements with Medtronic are expected to be exited by 2027.

Bullish Signals
  • MiniMed expanded its collaboration with Abbott to develop dual glucose-ketone sensors designed to integrate with MiniMed's smart dosing systems.
  • Abbott recently received Europe's CE mark for a dual glucose-ketone sensor, indicating regulatory progress despite pending FDA clearance.
  • MiniMed secured FDA clearance for the smaller durable insulin pump, MiniMed Flex, which is scheduled to launch later this month.
  • The company successfully launched MiniMed Go, a system combining a smart insulin pen with a glucose sensor, in the U.S. last week.
  • CEO Que Dallara confirmed that enrollment in the pivotal trial for Vivera, an automated insulin delivery algorithm removing meal announcement requirements, is halfway to its target.
  • MiniMed expects to submit its first insulin patch pump to the FDA this fall with plans for a commercial launch next year.
  • The company is actively scaling up production capacity ahead of the planned patch pump launch to meet future demand.
Risk Factors
  • Abbott's dual glucose-ketone sensor has not yet received FDA clearance despite having CE mark approval in Europe, creating regulatory uncertainty for the partnership.
  • MiniMed plans to submit its first insulin patch pump to the FDA this fall with a commercial launch targeted for next year, indicating it is entering a competitive market where Insulet already holds an established position.
Full Analysis
MiniMed, the diabetes technology spinoff from Medtronic, announced significant product and partnership developments during its first earnings call following its March IPO. The company is expanding its collaboration with Abbott to develop dual glucose-ketone sensors that will integrate with MiniMed's smart dosing systems; Abbott recently received CE mark approval for such a sensor in Europe, though FDA clearance is still pending. Additionally, MiniMed launched its smaller durable insulin pump, the MiniMed Flex, which received FDA clearance in March and is scheduled to launch later this month, alongside the recent U.S. launch of the MiniMed Go system for multiple daily injections. Looking ahead, the company plans to submit an insulin patch pump to the FDA this fall with a commercial launch targeted for next year, aiming to compete with Insulet's established market position. CEO Que Dallara also highlighted progress on Vivera, an automated insulin delivery algorithm designed to eliminate the need for meal announcements or carbohydrate counting, noting that enrollment in its U.S. pivotal trial started in February and is now halfway to completion. CFO Chad Spooner provided updates on the separation from Medtronic, stating there are approximately 160 transitional service agreements expected to be exited by 2027 as the company completes its portfolio transformation.